


Inositol

<i>myo</i> -Inositol ^[1]	
	
Identifiers	
CAS number	87-89-8 ^[2] ✓
SMILES	
Properties	
Molecular formula	C ₆ H ₁₂ O ₆
Molar mass	180.16 g mol ⁻¹
Density	1.752 g/cm ³
Melting point	225-227 °C
✓ (what is this?) (verify) ^[3] Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)	
Infobox references	


Inositol or **cyclohexane-1,2,3,4,5,6-hexol** is a chemical compound with formula C₆H₁₂O₆ or (-CHOH-)₆, a sixfold alcohol (polyol) of cyclohexane. It exists in nine possible stereoisomers, of which the most prominent form, widely occurring in nature, is *cis*-1,2,3,5-*trans*-4,6-cyclohexanehexol, or *myo*-inositol . Inositol is a carbohydrate, though not a classical sugar. It is almost tasteless, with a small amount of sweetness.

Myo-inositol plays an important role as the structural basis for a number of secondary messengers in eukaryotic cells, including inositol phosphates, phosphatidylinositol (PI) and phosphatidylinositol phosphate (PIP) lipids. In plants, the hexaphosphate of inositol is found as phytic acid. Inositol or its phosphates and associated lipids are found in many foods, in particular, in cereals with high bran content, nuts, beans, and fruit, especially cantaloupe melons and oranges.

Myo-Inositol was once classified as a member of the vitamin B complex . However, because it is produced by the human body from glucose, it is not an essential nutrient. Some substances such as niacin can also be synthesized in the body, but are not made in amounts considered adequate for good health, and thus are still classified as essential nutrients. However, there is no convincing evidence that this is the case for *Myo*-inositol.

Isomers and structure

Besides *myo*-inositol, the other naturally occurring isomers (though in minimal quantities) are *scyllo*-, *muco*-, **D-*chiro***-, and *neo*-inositol. The other possible isomers are **L-*chiro***-, **allo**-, **epi**-, and **cis-*inositol***.



In its most stable conformational geometry, the *myo*-inositol isomer assumes the chair conformation, which puts the maximum number of hydroxyls to the equatorial position, where they are farthest apart from each other. In this conformation the natural *myo* isomer has a structure in which five of the six hydroxyls (the 1st, 3rd, 4th, 5th, and 6th are equatorial, whereas the 2nd hydroxyl group is axial.^[4]

Synthesis

Myo-Inositol is synthesized from glucose-6-phosphate (G-6-P) in two steps. First, G-6-P is isomerised by ISYNA1 to *myo*-inositol 1-phosphate, which is then dephosphorylated by IMPase 1 to give free *myo*-inositol. In humans most inositol is synthesized in the kidneys, in typical amounts of a few grams per day.

Function

Inositol and a number of its mono and polyphosphates function as the basis for a number of signaling and secondary messenger molecules. They are involved in a number of biological processes, including:

- Insulin signal transduction^[5]
- Cytoskeleton assembly
- Nerve guidance (Epsin)
- Intracellular calcium (Ca²⁺) concentration control^[6]
- Cell membrane potential maintenance
- Serotonin activity modulation
- Breakdown of fats and reducing blood cholesterol
- Gene expression^[7] ^[8]

Phytic acid in plants

Phytic acid, which is **inositol hexakisphosphate (IP6)**, also known as **phytate** when in salt form, is the principal storage form of phosphorus in many plant tissues, especially bran and seeds.^[9]

Inositol penta- (IP5), tetra- (IP4), and triphosphate (IP3) are also called "phytates."

Clinical implications

Psychiatric conditions

Some preliminary results of studies on high dose inositol supplements show promising results for people suffering from problems such as bulimia, panic disorder, obsessive-compulsive disorder, agoraphobia, and unipolar and bipolar depression.^{[10] [11] [12] [13]}

In a single double-blind study on 13 patients, *Myo*-inositol has been found to reduce the symptoms of obsessive-compulsive disorder (OCD) significantly, with effectiveness equal to SSRIs and virtually without side-effects.^[14] In a double-blind, controlled trial, *myo*-inositol was superior to fluvoxamine for decreasing the number of panic attacks and had fewer side effects.^[12]

Patients suffering from clinical depression generally have decreased levels of inositol in their cerebrospinal fluid.^[10]^[11] A double-blind, placebo-controlled study of depressed patients showed that a high dose of inositol (12 grams daily) resulted in significant improvement of symptoms, with no changes noted in liver, kidney, or hematological function.^{[10] [11] [13]} A meta-analysis of randomized trials of inositol for depression was not able to determine if inositol is of benefit.^[15]

Research suggests that lithium functions primarily by decreasing *myo*-inositol concentrations in bipolar patients.^[16]^[17] Other studies suggest that lithium treatment may further inhibit the enzyme inositol monophosphatase leading to higher intracellular levels of inositol triphosphate,^[18] an effect which was enhanced further by administration of an inositol triphosphate reuptake inhibitor.

Other conditions

D-chiro-inositol (DCI) has been found in two double-blind studies to be an effective treatment for many of the clinical hallmarks of polycystic ovary syndrome (PCOS), including insulin resistance, hyperandrogenism, and oligo-amenorrhea.^{[19] [20]} The impetuses for these studies were the observed defects in DCI metabolism in PCOS and the implication of DCI in insulin signal transduction.^{[5] [21]}

Animal studies suggest inositol reduces the severity of the osmotic demyelination syndrome if given prior to rapid correction of chronic hyponatraemia.^[22] Further study is required prior to its application in humans for this indication.

Studies from *in vitro* experiments, animal studies, and limited clinical experiences, claim that inositol may be used effectively against some types of cancer, in particular, when used in combination with phytic acid.^[23]

Common use as a "cutting" agent

Inositol has been used as an adulterant (or cutting agent) in many illegal drugs, such as cocaine, methamphetamine, and sometimes heroin.^[24] This use is presumably connected with the substance's solubility and near-lack of taste (which is easily hidden by the chemical substance).

Nutritional sources

Myo-inositol is naturally present in a variety of foods.^[25] According to research, foods containing the highest concentrations of myo-inositol include fruits, beans, grains, and nuts.^[25]

See also

- Allo-inositol
- Cis-inositol
- D-chiro-inositol
- Epi-inositol
- L-chiro-inositol
- Muco-inositol
- Neo-inositol
- Scyllo-inositol
- Inositol 1-methyltransferase
- Inositol 3-methyltransferase
- Inositol 4-methyltransferase
- Inositol nicotinate
- Inositol phosphate
- Inositol trisphosphate
- Inositol pentakisphosphate
- Inositol hexaphosphate
- Inositol triphosphate receptor
- Inositol hexanicotinate
- Essential nutrient
- Hyperuricemia
- Hypouricemia

External links

- *Cancer Inhibition by Inositol Hexaphosphate (IP6) and Inositol: From Laboratory to Clinic* (scientific publication)^[26]
- *Myo-inositol Content of Various Foods*^[27]
- U.S. National Library of Medicine: Drug Information Portal - Inositol^[28]

References

- [1] *Merck Index*, 11th Edition, **4883**.
- [2] <http://www.commonchemistry.org/ChemicalDetail.aspx?ref=87-89-8>
- [3] <http://en.wikipedia.org/wiki/>
- [4] *The Chemical and Bio-physical properties of Phosphatidylinositol phosphates*, Thesis for M.Res.. Imperial College London. 2006.
- [5] Larner J (2002). "D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance" (<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2478565>). *Int J Exp Diabetes Res* **3** (1): 47–60. doi:10.1080/15604280212528. PMID 11900279. PMC 2478565.
- [6] Gerasimenko, Julia V; et al; "Bile Acids Induce Ca²⁺ Release from Both the Endoplasmic Reticulum and Acidic Intracellular Calcium Stores through Activation of Inositol Trisphosphate Receptors and Ryanodine Receptors"; *Journal of Biological Chemistry*; December 29, 2006; Volume 281: Pp 40154-40163.
- [7] Shen, X.; Xiao, H; Ranallo, R; Wu, WH; Wu, C (2003). "Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates". *Science* **299** (5603): 112–4. doi:10.1126/science.1078068. PMID 12434013.
- [8] Steger, D. J.; Haswell, ES; Miller, AL; Wentz, SR; O'Shea, EK (2003). "Regulation of chromatin remodelling by inositol polyphosphates" (<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1458531>). *Science* **299** (5603): 114–6. doi:10.1126/science.1078062. PMID 12434012. PMC 1458531.
- [9] Phytic acid (<http://www.phytochemicals.info/phytochemicals/phytic-acid.php>)
- [10] Nick, Gina L. (2004). "Inositol as a treatment for psychiatric disorders: a scientific evaluation of its clinical effectiveness" (http://findarticles.com/p/articles/mi_m0ISW/is_255/ai_n6211958). (*indirect through findarticles.com*) *Townsend Letter for Doctors and Patients* (October). . Retrieved 2008-05-24.
- [11] Nick, Gina L. (2004). "Inositol as a treatment for psychiatric disorders" (<http://www.townsendletter.com/Oct2004/Oct2004.htm>). (*direct*) *Townsend Letter; the Examiner of Alternative Medicine* (October). .

- [12] Palatnik A, Frolov K, Fux M, Benjamin J (2001). "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder". *Journal of Clinical Psychopharmacology* **21** (3): 335–339. doi:10.1097/00004714-200106000-00014. PMID 11386498.
- [13] Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. (1995). "Double-blind, controlled trial of inositol treatment of depression". *American Journal of Psychiatry* **152** (5): 792–794. PMID 7726322.
- [14] Fux M, Levine J, Aviv A, Belmaker RH (1996). "Inositol treatment of obsessive-compulsive disorder". *American Journal of Psychiatry* **153** (9): 1219–21. PMID 8780431.
- [15] Taylor MJ, Wilder H, Bhagwagar Z, Geddes J (2004). "Inositol for depressive disorders". *Cochrane Database Syst Rev* (2): CD004049. doi:10.1002/14651858.CD004049.pub2. PMID 15106232.
- [16] "Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings" (<http://cat.inist.fr/?aModele=afficheN&cpsidt=16522328>). .
- [17] "Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited" (<http://www.nature.com/mp/journal/v10/n1/full/4001618a.html>). .
- [18] Einat H, Kofman O, Itkin O, Lewitan RJ, Belmaker RH (1998). "Augmentation of lithium's behavioral effect by inositol uptake inhibitors" (<http://link.springer.de/link/service/journals/00702/bibs/8105001/81050031.htm>). *J Neural Transm* **105** (1): 31–8. doi:10.1007/s007020050035. PMID 9588758. .
- [19] Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G (1999). "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome". *N Engl J Med* **340** (17): 1314–1320. doi:10.1056/NEJM199904293401703. PMID 10219066.
- [20] Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E (2002). "Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome". *Endocr Pract* **8** (6): 417–423. PMID 15251831.
- [21] Nestler J E, Jakubowicz D J, Iuorno M J (2000). "Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome". *J Pediatr Endocrinol Metab* **13 Suppl 5**: 1295–1298. PMID 11117673.
- [22] Silver SM, Schroeder BM, Sterns RH, Rojiani AM (2006). "Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats". *J Neuropathol Exp Neurol* **65** (1): 37–44. doi:10.1097/01.jnen.0000195938.02292.39. PMID 16410747.
- [23] Vucenic, I; Shamsuddin, AM (2003). "Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic.". *The Journal of nutrition* **133** (11 Suppl 1): 3778S–3784S. PMID 14608114.
- [24] <http://www.examiner.com/x-281-Caffeine-Examiner~y2008m5d22-Ingredient-of-the-day-Guarana--Murdered-Child-Eyeballs>
- [25] Clements, Rex; Betty Darnell (1980). "Myo-inositol content of common foods: development of a high-myo-inositol diet" (<http://www.ajcn.org/cgi/reprint/33/9/1954.pdf>). *American Journal of Clinical Nutrition* **33** (9): 1954–1967. PMID 7416064. . Retrieved 2009-05-18.
- [26] <http://jn.nutrition.org/cgi/content/full/133/11/3778S>
- [27] <http://www.ajcn.org/cgi/reprint/33/9/1954.pdf>
- [28] <http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Inositol>

Article Sources and Contributors

Inositol *Source:* <http://en.wikipedia.org/w/index.php?oldid=380529321> *Contributors:* Alansohn, Alsocal, Amystroud, Anaraug, Anyeverybody, Apotheosis247, Beetstra, Benbest, Bobo192, BorisTM, CMBJ, Canar, Ccroberts, Celtus, ChangChienFu, Chem-awb, Chrysaor, Chuunen Baka, Circeus, Coppertwig, Davewho2, David Legrand, Drcarlos, Drphilharmonic, Edgar181, Faradayplank, Flowanda, Gerpfef, Ginkgo100, HazyM, Headybrew, Icairns, Ice-Nine, Ike9898, Ilikeeatingwaffles, Improbeat, J04n, Jake Wartenberg, JerryFriedman, John Nixon, Jon m, Jorge Stolfi, Koavf, Kslays, Kupirijo, Kyng, Lackinglatin, Lavateraguy, LiHHelpa, Lwieise, Madhero88, Marcelo1229, Masterpjz9, McBrainz, Mgsinc, Mister Handy, Moeron, MrOllie, Mrbrobertson, Msavidge, Mullet, Mundane123, Nono64, Ojcookies, PFHLai, Pharmaclees, Philcord, Probios, Quintote, Quinyu, Ragzter, Rich Farmbrough, Rifleman 82, Roadnottaken, Ronhjones, SJaneM, Sbharris, Shaddack, Shimari, Showjumpersam, Slashme, StaticVision, SteinAlive, Tartarus, Teuteul, Trikly, Ubertravis, Una Smith, Uthbrian, Vanv2642, WacoJacko, WhatamIdoing, Wk muriithi, WolfmanSF, WriterHound, Yikrazuul, 155 anonymous edits

Image Sources, Licenses and Contributors

Image:Inositol structure.png *Source:* http://en.wikipedia.org/w/index.php?title=File:Inositol_structure.png *License:* Public Domain *Contributors:* User:Edgar181

Image:Myo-inositol numbering.svg *Source:* http://en.wikipedia.org/w/index.php?title=File:Myo-inositol_numbering.svg *License:* Public Domain *Contributors:* User:Yikrazuul

File:Yes check.svg *Source:* http://en.wikipedia.org/w/index.php?title=File:Yes_check.svg *License:* Public Domain *Contributors:* User:Gmaxwell, User:WarX

File:myo-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Myo-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:scyllo-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Scyllo-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:muco-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Muco-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:chiro-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Chiro-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:neo-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Neo-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:allo-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Allo-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:epi-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Epi-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

File:cis-inositol.svg *Source:* <http://en.wikipedia.org/w/index.php?title=File:Cis-inositol.svg> *License:* Creative Commons Attribution 3.0 *Contributors:* Original uploader was Kupirijo at en.wikipedia

License

Creative Commons Attribution-Share Alike 3.0 Unported
<http://creativecommons.org/licenses/by-sa/3.0/>